Published in AIDS Weekly, October 8th, 2001
Epimmune anticipates that it will file an Investigational New Drug (IND) application for its initial vaccine candidate, a therapeutic HIV vaccine, in the first quarter of 2002. Clinical trials could begin approximately one month later, pending FDA review. They stated that a pre-IND meeting was previously held in August 2001 with U.S. Food and Drug Administration (FDA) staff and representatives of the U.S. National Institutes of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.